warfarin genotyping

Research presented at the American College of Cardiology scientific session in Atlanta today suggests individuals who receive genetic testing early in their warfarin treatment are up to 31 percent less likely to be hospitalized than those who don't.

An AHRQ official provided updates on the agency's ongoing activities in the personalized medicine field, including the development of a BRCA testing decision-support tool; a draft report on frameworks for gauging genetic testing quality; and a randomized-controlled trial on pharmacogenomics warfarin dosing that is unlikely to change the standard of care.

Looking at approximately 326,000 SNPs in 1,053 Swedish subjects, the study is thought to be the first "sufficiently powered" trial to detect genome-wide significance of three SNPs. As a result, study authors note that "additional genes having a major influence on warfarin dose might not exist or be found in the near-term."

A paper appearing in today's issue of NEJM demonstrates that combining genetic and clinical data can improve stable warfarin dose predictions — especially for those taking high or low doses of the drug. Now, large clinical trials in the US and Europe are slated to test the effect such dosing improvements have on clinical outcomes.

Pages

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

In Science this week: in vitro generation of human reproductive cells, and more.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.